Subject:
All Disciplines Arts & Humanities Biology & Life Sciences Business & Economics Chemistry & Materials Science Computer Science & Mathematics Engineering Environmental & Earth Sciences Medicine & Pharmacology Physical Sciences Public Health & Healthcare Social Sciences
Sort:
Hottest Latest Alphabetical (A-Z) Alphabetical (Z-A)
Type:
All Topic Review Biography
Topic Review
Neuromyelitis Optica Spectrum Disorders
Neuromyelitis optica spectrum disorders (NMOSD) are a heterogeneous group of monophasic or recurrent autoinflammatory diseases of the central nervous system (CNS).
  • 404
  • 02 Feb 2021
Topic Review
Neuronal Nitric Oxide Synthase in Central Nervous System
The dysregulated activation of nNOS in neurons is critical in the development of different conditions affecting the SNC. An excessive production of NO by nNOS is responsible for a number of proteins’ posttranslational modifications (PTMs) which can lead to aberrant biochemical pathways, impairing the SNC functions. Researchers briefly revised the main implications of the dysregulated nNOS activation in the progression of the most prevalent CNS diseases, suggesting that compounds able to modulate the nNOS activity could be  promising therapeutics to tackle different neuronal pathologic conditions.
  • 307
  • 10 Oct 2023
Topic Review
Neuropeptides Inhibitors for Colorectal Cancer
Neuropeptides are mainly secreted from the human central and peripheral nervous systems. Neuropeptides bind to its cognate rhodopsin-like G-protein coupled receptor (GPCR) and perform various physiological functions. Conventional cancer treatments in clinical practice still present many drawbacks due to the lack of selectivity toward the target cell, drug-resistance, and side-effects, thus pushing for the development of new therapeutic agents and therapies. Recent research suggests that neuropeptides influence cancer cell proliferation, invasion, metastasis, and angiogenesis and, therefore, they could be exploited as a target for novel anticancer therapies. Very recently, targeted approaches that inhibit neuropeptides and their associated receptors are being developed in cancer treatment. 
  • 352
  • 29 Sep 2022
Topic Review
Neuroprotective Agents from Syzygium from Alzheimer’s Perspective
Alzheimer’s disease (AD) is the most prevalent type of dementia worldwide, constituting 70–80% of cases, primarily among the elderly. This irreversible neurodegenerative disorder progressively impairs memory and other cognitive functions. The molecular mechanisms of Syzygium species in neuroprotection include the inhibition of acetylcholinesterase (AChE) to correct cholinergic transmission, suppression of pro-inflammatory mediators, oxidative stress markers, reactive immediate species (RIS) production, enhancement of antioxidant enzymes, the restoration of brain ions homeostasis, the inhibition of microglial invasion, the modulation of ß-cell insulin release, the enhancement of lipid accumulation, glucose uptake, and adiponectin secretion via the activation of the insulin signaling pathway. Additional efforts are warranted to explore less studied species, including the Australian and Western Syzygium species. The effectiveness of the Syzygium genus in neuroprotective responses is markedly established, but further compound isolation, in silico, and clinical studies are demanded. 
  • 583
  • 14 Jun 2022
Topic Review
Neurotensin and Neurotensin Receptors
The tridecapeptide neurotensin (NT) was isolated from the bovine hypothalamus. It is involved in gut motility and belongs to a family of bioactive peptides, including contulakin, xenopsin, LANT-6, and neuromedin, showing similar amino acid sequences at the C-terminal region; this sequence is essential for the physiological effects mediated by these peptides. Neurotensin is relevant in brain reward mechanisms. Its role in substance abuse needs to be explored in depth to open new therapeutic strategies.
  • 551
  • 17 May 2023
Topic Review
New Discovered Molecules of COVID-19
New molecules/drugs are discovered by humans for the therapeutic management of new diseases or to address existing health challenges. New molecules/drugs require extensive clinical investigations, followed by approval from drug regulatory agencies for marketing.
  • 804
  • 13 Feb 2023
Topic Review
New Flavonoid & Myo-Inositol Supplement
Background and Aim. Cardiovascular risk is increased in women with menopause and metabolic syndrome. Aim of this study was to test the effect of a new supplement formula, combining cocoa polyphenols, myo-inositol, and soy isoflavones, on some biomarkers of cardiovascular risk in postmenopausal women with metabolic syndrome.Methods and Results. A total of 60 women were enrolled and randomly assigned (n=30per group) to receive the supplement (NRT: 30 mg of cocoa polyphenols, 80 mg of soy isoflavones, and 2 gr of myo-inositol), or placebo for 6 months. The study protocol included three visits (baseline, 6, and 12 months) for the evaluation of glucose, triglycerides, and HDL-cholesterol (HDL-C), adiponectin, visfatin, resistin, and bone-specific alkaline phosphatase (bone-ALP). At 6 months, a significant difference between NRT and placebo was found for glucose (96±7versus108±10 mg/dL), triglycerides (145±14versus165±18 mg/dL), visfatin (2.8±0.8versus3.7±1.1 ng/mL), resistin (27±7versus32±8 µg/L), and b-ALP (19±7versus15±5 µg/mL). No difference in HDL-C concentrations nor in adiponectin levels between groups was reported at 6 months.Conclusions.The supplement used in this study improves most of the biomarkers linked to metabolic syndrome. This Trial is registered withNCT01400724.
  • 682
  • 01 Nov 2020
Topic Review
New Potential Heterocyclic Molecular Targeted Drugs
Heterocyclic compounds, which are made up of both carbon and non-carbon atoms, serve as a crucial structural foundation for numerous chemicals with pharmacological and biological value. The research on heterocyclic compounds is an important part of organic chemistry and is utilized extensively in many industries, especially medicine. Heterocyclic compounds serve as the main active ingredient in a variety of pharmaceuticals, including analgesics, anti-inflammatory drugs, anti-tubercular drugs, antihypertensives, antidepressants, and even anticancer drugs. Many novel heterocyclic targeted drugs have emerged.Molecular targeted therapy is a key element of the new era of comprehensive multidisciplinary cancer treatment. A considerable number of molecular targeted medications have been created as part of the development of targeted therapy. 
  • 253
  • 25 Jun 2023
Topic Review
New Therapeutic Approaches in Treatment of Dyslipidaemia
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease. Traditional statin therapy remains the cornerstone therapeutic approach. Ezetimibe showed good but limited results when used in combination with statins. Bempedoic acid has been thoroughly studied in multiple clinical trials, with a reduction in LDL cholesterol by approximately 15%. The first approved monoclonal antibodies for the treatment of dyslipidaemia, PCSK9 inhibitors, are currently used as second-line treatment for patients with unregulated lipid levels on statin or statin combination therapy. A new siRNA molecule, inclisiran, demonstrates great potential, particularly concerning compliance, as it is administered twice yearly and pelacarsen, an antisense oligonucleotide that targets lipoprotein(a) and lowers its levels. Volanesorsen is the first drug that was designed to target chylomicrons and lower triglyceride levels, and olezarsen, the next in-line chylomicron lowering agent, is currently being researched. The newest possibilities for the treatment of dyslipidaemia are ANGPTL3 inhibitors with evinacumab, already approved by the FDA, and EMA for the treatment of familial hypercholesterolemia. 
  • 472
  • 12 Aug 2022
Topic Review
New Therapeutical Approaches for COVID-19
The pandemic of coronavirus disease (COVID-19) stimulated an unprecedented international collaborative effort for rapid diagnosis, epidemiologic surveillance, clinical management, prevention, and treatment. Since the beginning of the COVID-19 pandemic, treatment of the SARS-CoV-2 infection was a real challenge. An overview of the viral structure and life cycle of SARS-CoV-2 is given and future therapeutical options are discussed.
  • 510
  • 08 Jun 2022
  • Page
  • of
  • 106
Featured Entry Collections
>>

Featured Books

>>
Encyclopedia of Social Sciences
Encyclopedia of COVID-19
Encyclopedia of Fungi
Encyclopedia of Digital Society, Industry 5.0 and Smart City
Video Production Service
Feedback